• Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management

INCHEON, South Korea, Dec. 17, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its continued recognition by the Dow Jones Sustainability World Index (DJSI), a globally recognized benchmark for evaluating the sustainability performance of over 2,500 publicly traded companies.

Samsung Biologics was recognized for its dedication to embed sustainable business practices across its operations, particularly robust environmental efforts, including progress toward achieving net-zero emissions and an enhanced focus on carbon reduction across the value chain. The company has been listed for four consecutive years.

"This achievement demonstrates our commitment to driving sustainability across our operations and the broader biopharma value chain," said John Rim, President and CEO of Samsung Biologics. "We remain focused on delivering meaningful progress toward a net-zero future while supporting our clients and partners with their ESG goals and contribute to a healthier world."

Samsung Biologics continues to advance ESG initiatives, including its leadership role within the Sustainable Markets Initiative (SMI). As a champion of the Supply Chains Working Group in the SMI Health Systems Task Force, the company actively engages global suppliers to decarbonize and build more resilient value chains. The global CDMO is accelerating transition to renewable energy through its Power Purchase Agreement, Renewable Energy Certificate, also having completed Product Carbon Footprint measurements to support our clients in achieving net-zero. This year, Samsung Biologics joined the Pharmaceutical Supply Chain Initiative and also received an EcoVadis platinum sustainability rating.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are CGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics offers a combined 604 kL total capacity. The company launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025, adding 180 kL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in a dedicated antibody-drug conjugate (ADC) facility, mRNA technologies, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.

Samsung Biologics Media Contact
Claire Kim, Head of Global Marketing Communication
cair.kim@samsung.com